<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02708394</url>
  </required_header>
  <id_info>
    <org_study_id>MMAAPWSU</org_study_id>
    <nct_id>NCT02708394</nct_id>
  </id_info>
  <brief_title>Molecular Mechanisms of Antipsychotic-induced Insulin Resistance</brief_title>
  <official_title>Molecular Mechanisms of Antipsychotic-induced Insulin Resistance in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the molecular mechanisms of atypical-antipsychotic induced
      insulin resistance. This will be accomplished by administering olanzapine or placebo to
      healthy subjects for 7 days and analyzing genetic and protein changes in peripheral tissues
      known to play an important role in insulin resistance pathophysiology.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in DNA methylation</measure>
    <time_frame>Baseline (day 1) to endpoint of intervention (day 7)</time_frame>
    <description>Change in peripheral tissue candidate gene methylation will be measured in the olanzapine intervention group compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in protein levels</measure>
    <time_frame>Baseline (day 1) to endpoint of intervention (day 7)</time_frame>
    <description>Change in peripheral tissue candidate protein levels will be measured in the olanzapine intervention group compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in protein activity</measure>
    <time_frame>Baseline (day 1) to endpoint of intervention (day 7)</time_frame>
    <description>Change in peripheral tissue candidate protein phosphorylation will be measured in the olanzapine intervention group compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Adverse Effect of Other Antipsychotics and Neuroleptics</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atypical antipsychotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>atypical antipsychotic</description>
    <arm_group_label>olanzapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo control</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        We will include persons that meet the following criteria:

          1. 21-45 years old

          2. BMI 18.5-24.9kg/m2

          3. No history of drug or alcohol dependence or abuse

          4. No current or past history of psychiatric or neurologic disease

          5. minimal exercise routine prior or during study (light walking allowed)

          6. Normal liver function tests and 7) minimal alcohol intake (&lt;1 drink per day).

        The following persons will be excluded:

          1. Has 1st degree relative with diabetes (I or II)

          2. current or re-cent nicotine intake

          3. presence of organic/physical disease that could affect glucose

          4. currently taking prescription or over-the-counter medications that could affect
             glucose

          5. currently pregnant or lactating

          6. unwilling to take acceptable birth control method

          7. current or previous exposure to antipsychotics

          8. history of unstable weight

          9. personal or family history of cardiac arrhythmias or seizures

         10. current or past history of eating disorder(s) or restricted diet

         11. allergy to lidocaine or drug excipients

         12. history of difficulty with intravenous line placement

         13. history of fainting.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyle J Burghardt, Pharm.D.</last_name>
    <phone>313-577-3132</phone>
    <email>kburg@wayne.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elani Sanders</last_name>
    <phone>313-577-1379</phone>
    <email>pgxresearch@wayne.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wayne State University Clinical Research Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Parker</last_name>
    </contact>
    <investigator>
      <last_name>Kyle J Burghardt, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2016</study_first_submitted>
  <study_first_submitted_qc>March 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2016</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>Kyle Burghardt</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

